drugset
drugset / Trial / NCT02478320

Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

NCT02478320 ↗

Phase 2 Terminated 12 enrolled M.D. Anderson Cancer Center AbbVie · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if ilorasertib (ABT-348) can help to control CDKN2A-deficient cancer. CDKN2A deficiency is a type of mutation (a genetic change). The safety of this drug will also be studied.

Timeline

Start
2016-08-05
Primary completion
2022-05-12
Completion
2022-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ilorasertib Small molecule 200 mg Oral

Indications

high grade malignant neoplasm